Solarvest BioEnergy Inc. (TSXV:SVS), Mr. Gerri Greenham is pleased to announce that the Chinese Patent Office has accepted claims for Solarvest’s cecropin based malaria biologic. This in addition to our Australian and USA issued patents. Third party trials were conducted at the Toronto University Health Network at MaRS generating data which furthered our research and IP program. We would like to thank Dr. Ian Crandall for his expertise and support. With the current global awareness of diseases malaria still remains one of the world’s most serious diseases.

Malaria is a life threatening, mosquito borne disease caused by Plasmodium parasites. According to the World Malaria Report of 2018 by the WHO there were 228 million estimated cases with 435,000 related deaths, recorded worldwide. Solarvest Inc. has developed a genetically expressed anti-parasitic protein that is useful in treating or preventing endoparasitic infections such as malaria. This proprietary technology is based around a group of anti-microbial proteins that were originally isolated from the circulatory system of mosquitos, known as cecropins. Cecropins are small, amphipathic proteins, which interact with the lipid membrane of parasites and bacteria, causing pore like structure to form, inhibiting growth. It was discovered that cercopins are upregulated in mosquitos that harbour the malaria parasite, making them a candidate therapeutic for the treatment and prevention of the disease. Solarvest’s genetically modified cecropin is designed to be more stable and active than the endogenous mosquito proteins, providing it with more time to exert its effect on the malarial parasite. The efficacy of the protein has been confirmed through oral trials in a mice model parasite challenge. This protein may offer an alternative to the serious side effects resulting from the present chemical malaria treatments and prophylactics. Global temperature increases may see the expansion of the present range of the mosquito strains carrying the malaria parasite. The cecropin treatment for malaria adds to the company’s track record of creating high value proteins like BMP **

About: SOLARVEST BIOENERGY INC. (TSX-V: SVS). The expression of therapeutic molecules, vaccines, and nutraceutical products are the foundation/output of Solarvest’s patented technology platform. Amongst its Research and Development projects, the company previously initiated a program with FSD Pharma: NASDAQ: HUGE for the expression of purified cannabinoid proteins – Press Release May 2019. This partnership was created to take advantage of the Solarvest technology, which is capable of producing to the stringent human Active Pharmaceutical Ingredient (API) quality standards. The Company will also release its first Omega-3 DHA nutraceutical product for children in 2020, a significant segment of the Ocean based Omega-3 market, that exceeds $20 billion* globally.

For further information contact:

Gerri Greenham, Chief Executive Officer

Tel: 416 420 0947 Email:

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

* *GOED Omega 3 Market Presentation -2012 Estimated Global Consumer Spending on Products Containing EPA/DHA Oils.


Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.



Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!


Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products and Bluma Wellness Inc. (“Bluma Wellness”), a vertically integrated operator in Florida, today announced the closing of the Company’s previously announced acquisition of Bluma Wellness.

Transaction Highlights

Keep reading... Show less

Construction of New Facility Under Way

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce the appointment of commercial farming and construction expert, Josh Baker, to its Board of Directors today.

Keep reading... Show less

– Virtual Investor Conferences and KCSA Strategic Communications today announced the agenda for the upcoming KCSA Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Tuesday, April 20 th .

Keep reading... Show less

Launching Digital Sales Platform

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRD) (formerly Redfund Capital Corp.) (“Global” or the “Company”) announces KaleidoMyco agreement with digital marketing firm The Wolf of Marketing to launch digital sales platform.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Health and wellness, beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) recently announced that following the appointment of former Pepsi Co. executive, Melise Panetta to President of the organization. it has further bolstered its leadership team with veteran consumer packaged goods (“CPG”) expertise, which is anticipated to deepen and expand BevCanna’s existing sales and distribution network, and accelerate growth.

Keep reading... Show less